Pharma Leaders

Getting JUV-161 to Phase I in 2025

9 hours ago
Add Comment
by David Miller
945 Views

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Leave a Comment

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]